- Home
- NEOV vs CTOR Comparison
NEOV vs CTOR Comparison
Compare NEOV & CTOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEOV
- CTOR
- Stock Information
- Founded
- NEOV 2018
- CTOR 2021
- Country
- NEOV United States
- CTOR United States
- Employees
- NEOV N/A
- CTOR N/A
- Industry
- NEOV Industrial Machinery/Components
- CTOR
- Sector
- NEOV Miscellaneous
- CTOR
- Exchange
- NEOV Nasdaq
- CTOR NYSE
- Market Cap
- NEOV 72.2M
- CTOR 63.7M
- IPO Year
- NEOV N/A
- CTOR N/A
- Fundamental
- Price
- NEOV $4.54
- CTOR $2.87
- Analyst Decision
- NEOV Strong Buy
- CTOR Buy
- Analyst Count
- NEOV 1
- CTOR 2
- Target Price
- NEOV $7.50
- CTOR $6.00
- AVG Volume (30 Days)
- NEOV 177.8K
- CTOR 2.7M
- Earning Date
- NEOV 05-09-2025
- CTOR 08-11-2025
- Dividend Yield
- NEOV N/A
- CTOR N/A
- EPS Growth
- NEOV N/A
- CTOR N/A
- EPS
- NEOV N/A
- CTOR N/A
- Revenue
- NEOV $4,255,136.00
- CTOR N/A
- Revenue This Year
- NEOV $208.50
- CTOR N/A
- Revenue Next Year
- NEOV $128.75
- CTOR N/A
- P/E Ratio
- NEOV N/A
- CTOR N/A
- Revenue Growth
- NEOV 52.64
- CTOR N/A
- 52 Week Low
- NEOV $1.80
- CTOR $0.55
- 52 Week High
- NEOV $6.11
- CTOR $49.00
- Technical
- Relative Strength Index (RSI)
- NEOV 74.78
- CTOR N/A
- Support Level
- NEOV $3.10
- CTOR N/A
- Resistance Level
- NEOV $3.57
- CTOR N/A
- Average True Range (ATR)
- NEOV 0.35
- CTOR 0.00
- MACD
- NEOV 0.14
- CTOR 0.00
- Stochastic Oscillator
- NEOV 89.18
- CTOR 0.00
About NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About CTOR CITIUS ONCOLOGY INC
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.